Search Bar & Filters
Found 9 Actively Recruiting clinical trials
Actively Recruiting
Researchers are investigating the safety and effectiveness of a new device called the Alleviant ALV1 System, designed to create an interatrial shunt for patients with heart failure and reduced ejection fraction HFrEF. This prospective, randomized, double-blind, sham-controlled trial involves multiple centers and aims to compare the outcomes of patients receiving this device to those undergoing a sham procedure. The study focuses on those with heart failure who have a left ventricular ejection fraction of 40% or less and are classified as NYHA class II, III, or ambulatory IV. Participants are randomly assigned to one of two groups. The treatment group undergoes cardiac imaging, femoral vein access, and receives the Alleviant ALV1 System device procedure to create the interatrial shunt. The control group undergoes cardiac imaging and femoral vein sheath placement but does not receive the device. The study uses a crossover design, allowing comparison between the treatment and sham procedures under double-blind conditions. Throughout the study, participants will be monitored for safety and efficacy, with cardiac imaging used to assess outcomes. The primary outcome is a composite endpoint measured at 12 months, which evaluates the overall impact of the device on heart failure. The trial is sponsored by Alleviant Medical, Inc. and will continue until December 2028. Participants can expect regular assessments and follow-up visits during the study period.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of the Trilogy Transcatheter Heart Valve THV System compared with traditional surgical aortic valve replacement SAVR in patients with clinically significant native aortic regurgitation AR. The purpose is to demonstrate that the Trilogy system is not inferior to surgery for treating this heart valve condition. Participants will be randomly assigned to receive either Transcatheter Aortic Valve Replacement TAVR using the Trilogy THV System or SAVR using a commercially available surgical prosthetic valve. The study focuses on treatment of native valve predominant AR, with both methods delivered by specialized heart teams. The study will continue until 2036, with primary outcome measures assessed at 12 months. During the trial, participants will have follow-up visits to monitor outcomes such as all-cause mortality, stroke, and unplanned cardiac rehospitalization. Additional assessments include echocardiographic measurements, quality of life questionnaires, and adverse cardiovascular events over several years. Participants are expected to return for post-procedure visits to track safety and effectiveness through a variety of clinical and imaging evaluations.
Actively Recruiting
Researchers are evaluating whether ataciguat can slow the progression of moderate calcific aortic valve stenosis CAVS in adults aged 50 and older. This study is conducted in two parts Part A focuses on whether ataciguat reduces calcium buildup in the aortic valve over 24 weeks, while Part B examines if the drug slows narrowing of the valve area and improves peak oxygen consumption over 48 weeks. Safety, tolerability, and how the body processes ataciguat are also assessed. Participants receive either ataciguat or a placebo daily for up to 156 weeks. Part A enrolls about 132 participants, and Part B will begin after Part A completes, enrolling around 1144 participants. Part B includes additional evaluation of heart function and ability to exercise. The study uses a randomized, double-blind design, meaning neither participants nor researchers know who receives the drug or placebo. During the study, participants undergo imaging tests like CT scans and echocardiograms to measure valve calcium and valve area. Cardiopulmonary exercise testing CPET is used to assess peak oxygen consumption. Researchers also monitor heart function, symptoms, and quality of life using questionnaires. Assessments occur mainly at baseline, Week 24, and Week 48, with long-term follow-up to 156 weeks for safety and efficacy. The studys total duration extends to 2030.
Actively Recruiting
Researchers are evaluating the long-term safety and effectiveness of CCM therapy in treating heart failure in a real-world setting. This global, observational study includes both prospective and retrospective patients who have received or will receive CCM therapy using Impulse Dynamics systems, including future technologies such as CCM-D. Participants will be followed for at least 5 years to gather comprehensive data. Participants receive CCM therapy through an Impulse Dynamics device as part of their regular care. The study does not assign treatments but observes patients who have been implanted or will be implanted with these devices. The registry collects data from multiple centers worldwide, tracking outcomes over time without altering the standard treatment process. During the study, participants will be monitored regularly to assess hospitalizations related to heart failure, device- or procedure-related complications, mortality, functional capacity, and quality of life among other measures. Assessments include questionnaires like the Kansas City Cardiomyopathy Questionnaire and evaluations of clinical outcomes, device compliance, and cardiovascular changes. Follow-up will last for at least five years, ensuring long-term safety and effectiveness data collection.
Actively Recruiting
This research aims to collect real-world information about the treatment of lesions in the peripheral vasculature, focusing on patients who may not have been included in previous Peripheral Vascular Disease PVD studies. It evaluates the use of commercially available drug-eluting devices made by Boston Scientific Corporation to better understand their application and health economic impact globally. Participants in this registry receive treatment with Boston Scientific drug-eluting devices such as the Ranger14 Paclitaxel-Coated PTA Balloon Catheter and the ELUVIA14 Drug-Eluting Vascular Stent System. The study is observational and includes patients from multiple countries, with follow-up lasting up to 2 years in most countries and up to 5 years in China. Some participants at select sites will also complete additional assessments like quality of life questionnaires, six-minute walk tests, and healthcare utilization data collection. Throughout the study, participants undergo assessments based on standard care procedures. Researchers will monitor major adverse events and lesion patency at 12 months. Data collected includes health economics and patient outcomes to support the safe use of these devices. The total study duration extends up to 5 years depending on location, with scheduled follow-ups to gather ongoing information about treatment effects and patient health.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of the KARDION Cory P4 System in adults aged 18 to 90 years who require hemodynamic support during high-risk percutaneous coronary intervention PCI procedures for coronary artery disease. The trial aims to demonstrate outcomes within 30 days after the procedure, focusing on major adverse cardiac and cerebrovascular events MACCE and device-related safety. Participants are randomly assigned to receive one of two types of percutaneous mechanical circulatory support devices during the PCI procedure. The study compares the KARDION Cory P4 System with a commercial control device. Treatment is provided during the index PCI procedure, and follow-up continues for 30 days to assess technical and procedural success as well as any device-related adverse events. During the study, participants undergo evaluations including safety monitoring and outcome assessments up to 30 days post-procedure. Researchers measure device-related safety, major adverse cardiac events, death, and other health outcomes related to the intervention. Participants must comply with follow-up visits and evaluations as specified in the study protocol. The total participation duration includes the procedure and a 30-day follow-up period.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of a sirolimus drug coated balloon compared to standard balloon angioplasty for treating below the knee arterial disease. This pivotal, prospective, randomized, two-arm, placebo-controlled trial will be conducted at about 80 sites worldwide, including the USA, Europe, Australia, and Asia. The study addresses the high burden of limb loss caused by peripheral arterial disease and explores sirolimus as an alternative to paclitaxel for drug coated balloons below the knee. Participants will be randomly assigned in equal groups to receive either the MagicTouch PTA sirolimus coated balloon catheter plus standard balloon angioplasty or a placebo balloon angioplasty plus standard balloon angioplasty. All patients first receive pre-dilation with a standard balloon angioplasty. The sirolimus coated balloon is used as an additional treatment after successful lesion preparation. The trial is single-blind and multicenter, aiming to compare outcomes between these two treated groups. During the study, participants will undergo assessments including angiographic evaluations and monitoring of limb health. The primary outcome is primary patency at 12 months, defined by freedom from vessel occlusion, restenosis, target lesion revascularization, and major amputation. Safety will also be evaluated at 6 months and 30 days with composite endpoints. Secondary outcomes include various safety and efficacy measurements up to 60 months. This comprehensive follow-up will help assess long-term treatment effects and participant safety throughout the study period.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of the Carillon Mitral Contour System CMCS in treating patients with heart failure who also have functional mitral regurgitation FMR. This prospective, randomized, double-blinded, sham-controlled trial aims to better understand how this device may impact heart function and symptoms in people with this condition. Participants will be randomly assigned to one of two groups one group will receive the Carillon implant along with guideline-directed heart failure medications, while the other group will receive only the heart failure medications and a sham procedure to preserve blinding. Before randomization, patients will undergo specific heart imaging tests and evaluations to determine eligibility and suitability for the device placement. After the procedure, participants will have follow-up visits at 1, 6, 12, 18, and 24 months to monitor safety and heart function. After 24 months, all participants will be informed of their group assignment and followed annually for an additional three years. During the study, researchers will assess various health outcomes including freedom from major adverse events at 12 months and clinical improvement at 24 months. Additional measures will include changes in heart valve function, heart size, walking ability, heart failure symptoms, hospitalizations, and quality of life. Participants will have regular heart imaging, clinical evaluations, and questionnaires to track these outcomes. The total participation time may extend up to five years with long-term monitoring to better understand the devices impact over time.
Actively Recruiting
Researchers are evaluating the Thor system in adults aged 18 years and older who have new, untreated calcified blockages in leg arteries caused by peripheral artery disease PAD. The study aims to determine whether the Thor system is safe and effective for treating these lesions. Patients experience leg pain due to poor blood flow, and the study will observe how the Thor system works in this setting. All participants will receive treatment using the Thor laser atherectomy system, which targets calcified lesions to improve blood flow. During the procedure, doctors may also use additional devices such as angioplasty balloons, drug-coated balloons, stents, and clot-collecting filters if needed. The procedure includes x-ray imaging, and patients will be monitored closely until discharge or for up to 24 hours after treatment. Participants will have follow-up visits at discharge, 30 days, 6 months, and 12 months after the procedure. These visits include medical history reviews, physical exams of the legs, blood flow tests using arm and leg blood pressure comparisons, ultrasound imaging, and questionnaires about walking ability and quality of life. The study will measure outcomes such as freedom from major adverse events, procedural success, lesion openness, and improvements in walking and health surveys over one year.